ALLO (Allogene Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ALLO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-25 | Earl Martin Douglas | SVP, General Counsel | Sell | — | — |
| 2026-07-06 | Zachary Roberts | President and CEO | A | — | — |
| 2026-06-23 | VICKI L SATO | Director | A | — | — |
| 2026-06-23 | Franz B Humer | Director | A | — | — |
| 2026-06-23 | Stephen Mayo | Director | A | — | — |
| 2026-06-23 | Joshua A Kazam | Director | M | — | — |
| 2026-06-23 | Elizabeth A. Barrett | Director | A | — | — |
| 2026-06-23 | DEBORAH M. MESSEMER | Director | A | — | — |
| 2026-06-23 | OWEN N. WITTE | Director | A | — | — |
| 2026-04-23 | Annie Yoshiyama | SVP, Finance | Sell | — | — |
| 2026-04-02 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sell | — | — |
| 2026-03-18 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sell | — | — |
| 2026-03-18 | David D Chang | President and CEO | Sell | — | — |
| 2026-03-04 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sell | — | — |
| 2026-02-04 | Geoffrey M. Parker | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2026-02-04 | Zachary Roberts | EVP of R&D | Sell | — | — |
| 2026-02-04 | Annie Yoshiyama | SVP, Finance | Sell | — | — |
| 2026-02-04 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sell | — | — |
| 2026-02-04 | David D Chang | President and CEO | Sell | — | — |
| 2026-02-04 | Arie Belldegrun | Director | A | — | — |
| 2026-02-04 | Earl Martin Douglas | SVP, General Counsel | Sell | — | — |
| 2026-01-23 | Zachary Roberts | EVP of R&D | Sell | — | — |
| 2025-12-22 | Joshua A Kazam | Director | M | — | — |
| 2025-11-19 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sell | — | — |
| 2025-10-23 | Geoffrey M. Parker | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2025-06-23 | Stephen Mayo | Director | A | — | — |
| 2025-06-23 | Elizabeth A. Barrett | Director | A | — | — |
| 2025-06-23 | OWEN N. WITTE | Director | A | — | — |
| 2025-06-23 | VICKI L SATO | Director | A | — | — |
| 2025-06-23 | DEBORAH M. MESSEMER | Director | A | — | — |
| 2025-06-23 | Joshua A Kazam | Director | A | — | — |
| 2025-06-23 | Franz B Humer | Director | A | — | — |
| 2025-06-12 | DEBORAH M. MESSEMER | Director | Sell | — | — |
| 2025-04-23 | Annie Yoshiyama | SVP, Finance | Sell | — | — |
| 2025-03-18 | David D Chang | President and CEO | Sell | — | — |
| 2025-03-18 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sell | — | — |
| 2025-03-05 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | A | — | — |
| 2025-02-20 | DEBORAH M. MESSEMER | Director | Sell | — | — |
| 2025-02-05 | TIMOTHY L. MOORE | Chief Technical Officer | Sell | — | — |
| 2025-02-05 | Geoffrey M. Parker | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2025-02-05 | Zachary Roberts | EVP of R&D | Sell | — | — |
| 2025-02-05 | Earl Martin Douglas | SVP, General Counsel | Sell | — | — |
| 2025-02-05 | David D Chang | President and CEO | Sell | — | — |
| 2025-01-28 | Geoffrey M. Parker | CHIEF FINANCIAL OFFICER | A | — | — |
| 2025-01-28 | Annie Yoshiyama | SVP, Finance | A | — | — |
| 2025-01-28 | Zachary Roberts | EVP of R&D | A | — | — |
| 2025-01-28 | Earl Martin Douglas | SVP, General Counsel | A | — | — |
| 2025-01-28 | David D Chang | President and CEO | A | — | — |
| 2025-01-28 | Arie Belldegrun | Director | A | — | — |
| 2025-01-23 | Zachary Roberts | EVP of R&D | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 21,976,484 | — |
| — | Director | 20,728,904 | — |
| — | 10%+ Owner | 19,776,053 | — |
| — | 10%+ Owner | 18,723,992 | — |
| — | President and CEO | 6,006,643 | — |
| — | Director | 4,034,979 | — |
| — | Chief Financial Officer | 2,015,034 | — |
| — | CHIEF FINANCIAL OFFICER | 1,252,795 | — |
| — | Chief Technical Officer | 672,731 | — |
| — | President and CEO | 581,166 | — |
| — | General Counsel | 556,049 | — |
| — | EVP of R&D | 541,946 | — |
| — | SVP, General Counsel | 488,267 | — |
| — | Director | 398,463 | — |
| — | Director | 307,507 | — |
| — | Director | 292,832 | — |
| — | Chief Technical Officer | 250,713 | — |
| — | SVP, Chief Technical Officer | 195,338 | — |
| — | Director | 162,575 | — |
| — | VP, Corporate Counsel | 140,390 | — |
| — | SVP, Finance | 124,517 | — |
| — | Director | 113,966 | — |
| — | SVP, Finance | 88,881 | — |
| — | Director | 25,328 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ALLO quote page; the site-wide leaderboard is on the insider transactions hub.